{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-016678","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.059212+00:00","generated_at":"2026-05-27T00:02:13.716544+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Axsome settles AUVELITY patent litigation with Teva; generic entry no earlier than 2038-2039","bullets":["Settlement grants Teva license to sell generic AUVELITY starting Mar 31, 2039 (if pediatric exclusivity) or Sep 30, 2038 (if not).","All ongoing AUVELITY patent litigation in U.S. District Court for New Jersey will be terminated.","Agreement is subject to review by the U.S. FTC and U.S. Department of Justice.","CEO Herriot Tabuteau says settlement reflects strength of Axsome’s IP portfolio and commitment to CNS innovation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-016678","json":"https://secwatch.observer/filing/0000950170-25-016678.json","markdown":"https://secwatch.observer/filing/0000950170-25-016678.md","text":"https://secwatch.observer/filing/0000950170-25-016678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025016678/0000950170-25-016678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025016678/axsm-20250210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:02:13.716544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}